Latest news with #AlumniCapital
Yahoo
23-05-2025
- Business
- Yahoo
Oncolytics Biotech Inc (ONCY) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ...
Cash and Cash Equivalents: $15.3 million as of March 31, 2025. Net Cash Operating Activities: $6.5 million for the quarter, down from $7.5 million in the same period last year. General and Administrative Expenses: $3 million for the first quarter, consistent with the prior year. Research and Development Expenses: $4.1 million, down from $5.7 million in Q1 of 2024. Net Loss: $6.7 million or $0.08 per basic and diluted share, compared to $6.9 million or $0.09 per share in Q1 of 2024. Share Purchase Agreement: USD20 million agreement with Alumni Capital to extend financial runway. Warning! GuruFocus has detected 1 Warning Sign with ONCY. Release Date: May 14, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Oncolytics Biotech Inc (NASDAQ:ONCY) reported promising clinical data for pelareorep, showing a 33% objective response rate in relapsed anal carcinoma, including a complete response lasting over 15 months. The company is actively enrolling patients in the GOBLET Cohort 5 study for metastatic pancreatic cancer, supported by a $5 million grant from the Pancreatic Cancer Action Network. Pelareorep demonstrated a favorable safety profile across multiple studies, allowing for combination with various chemotherapies and checkpoint inhibitors. The company has secured a USD20 million share purchase agreement with Alumni Capital, providing financial flexibility and extending the runway through key milestones. Oncolytics Biotech Inc (NASDAQ:ONCY) is exploring multiple registrational opportunities for pelareorep in breast cancer, supported by positive data from two randomized Phase 2 studies showing significant clinical benefits. The company is still in the process of searching for a new CEO, which may impact strategic decision-making and leadership continuity. Despite promising data, regulatory approval for pelareorep in anal carcinoma is not guaranteed and the commercial opportunity is smaller compared to other indications. Research and development expenses decreased due to reduced manufacturing and clinical trial costs, which could indicate a slowdown in certain development activities. The net loss for the quarter was $6.7 million, reflecting ongoing financial challenges despite a slight improvement from the previous year. There have been no recent interactions with the FDA regarding the pancreatic cancer program, which could delay potential registrational pathways. Q: Regarding the anticipated start of the registrational trial in HR positive HER2 negative metastatic breast cancer, what can you share about the potential trial design for the study? Will PFS be a primary endpoint? And have there been any recent interactions with the FDA regarding the pancreatic cancer program? A: Thomas Heineman, Chief Medical Officer, explained that the primary endpoint for the breast cancer study is anticipated to be progression-free survival. The FDA has been informed of the pancreatic cancer program, and while there have been no recent discussions, the FDA granted Fast Track approval in pancreatic cancer. Q: Are there specific areas like regional rights or co-development opportunities being prioritized in business development activities? Are there plans to explore additional combination approaches with immune checkpoint inhibitors? A: Christophe Degois, VP of Business Development, stated that they are exploring both global and regional partnerships, particularly for breast and pancreatic cancer. Thomas Heineman added that they are exploring combinations with checkpoint inhibitors, especially in pancreatic cancer, where there is strong synergy. Q: Could you discuss the rationale and potential registration paths for treating patients at different stages of the breast cancer journey? A: Thomas Heineman clarified that while they are not shifting focus to earlier stages, there are opportunities in treating patients who have failed antibody-drug conjugate therapy. This could further de-risk the program and stimulate interest from partners and investors. Q: Can you describe the basic structure of the share purchase agreement with Alumni Capital and the flexibility it offers? A: Kirk Look, CFO, explained that the agreement provides access to capital at their discretion, with a minimum purchase notice set at $750,000. This structure helps reduce the cost of capital and supports strategic program advancements. Q: Have you utilized the share purchase agreement since its announcement? A: Kirk Look confirmed that they have tapped into the agreement strategically to ensure it functions as intended. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
Yahoo
22-05-2025
- Business
- Yahoo
VCI Global Revises Equity Agreement with 102% Premium Pricing, Enhancing Strategic Flexibility
Amended Terms with Alumni Capital Reinforce Disciplined Capital Deployment and Long-Term Growth Priorities KUALA LUMPUR, Malaysia, May 22, 2025 (GLOBE NEWSWIRE) -- VCI Global Limited (NASDAQ: VCIG) ('VCI Global'), a diversified global holding company with a strategic focus on AI & Robotics, Fintech, Cybersecurity, Renewable Energy, and Capital Market Consultancy, today announced a significant amendment to its equity line agreement with Alumni Capital LP ('Alumni Capital'). The revised terms underscore VCI Global's disciplined capital strategy and reinforce its commitment to long-term shareholder value. Under the revised terms, any future equity issuance to Alumni Capital will be priced at 102% of the lowest trading price over the preceding five trading days, a notable improvement from the previous pricing of 85% of the same reference period. This shift reflects increased institutional confidence in VCI Global's growth trajectory and introduces a more shareholder-aligned capital structure. With these improved terms, the capital agreement now serves as a powerful financial lever, a liquidity reserve that enables the Company to capitalize on strategic acquisitions, accelerate platform initiatives, or respond swiftly to market dynamics. Importantly, the Company retains full discretion over drawdowns, ensuring capital is deployed only when conditions are optimal. VCI Global remains focused on disciplined, high-impact growth and long-term value creation. Key Terms of the Amended Facility Premium-Based Pricing: Future equity tranches will be priced at 102% of the lowest five-day trading price, replacing the previous 85% pricing model. This reduces dilution and strengthens shareholder alignment. Strategic Control: VCI Global retains the right, but not the obligation, to access the approximately US$112 million facility, enabling capital to be utilized only when strategically beneficial. Supports Scalable Growth: The revised terms complement VCI Global's aggressive expansion into AI infrastructure, cybersecurity, and capital markets advisory, while preserving financial flexibility. 'This revised pricing framework demonstrates a strong investor conviction in our long-term trajectory. It ensures that we retain the flexibility to act decisively while significantly minimizing dilution for existing shareholders. With these terms in place, we are better positioned to accelerate execution, protect value, and unlock scalable impact across our verticals,' said Dato' Victor Hoo, Group Executive Chairman and Chief Executive Officer of VCI Global. About VCI Global Limited VCI Global is a diversified global holding company with a strategic focus on AI & Robotics, Fintech, Cybersecurity, Renewable Energy, and Capital Market Consultancy. With a strong presence in Asia, Europe, and the United States, VCI Global is committed to driving technological innovation, sustainable growth, and financial excellence across multiple industries. For more information on the Company, please log on to Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company's ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words 'intends,' 'may,' 'will,' 'plans,' 'expects,' 'anticipates,' 'projects,' 'predicts,' 'estimates,' 'aims,' 'believes,' 'hopes,' 'potential' or similar words. These forward-looking statements are based only on our current beliefs, expectations, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of our control. Therefore, you should not rely on any of these forward-looking statements. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including without limitation, the Company's ability to achieve profitable operations, customer acceptance of new products, the effects of the spread of coronavirus (COVID-19) and future measures taken by authorities in the countries wherein the Company has supply chain partners, the demand for the Company's products and the Company's customers' economic condition, the impact of competitive products and pricing, successfully managing and, general economic conditions and other risk factors detailed in the Company's filings with the United States Securities and Exchange Commission ('SEC'). The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update the forward-looking statements in this release, except in accordance with applicable law. CONTACT INFORMATION: For media queries, please contact: VCI GLOBAL LIMITEDenquiries@ in to access your portfolio
